Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
RA’ANANA, Israel, May 11, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today that the Company has been selected for an oral podium presentation and a poster presentation at the upcoming American Urology Association 2017 Annual Meeting in Boston, Massachusetts from May 12 to May 16, 2017.
The oral podium and poster presentations are related to UroGen Pharma’s clinical stage uro-oncology product candidates, as detailed below:
Oral podium presentation: PD19-10: The Chemoablative Effect of VesiGel Instillation in Patients with NMIBC – Response Rate and One-Year Durability
Presenting Author: Andrew Lenis, MD MS, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California
Session: Bladder Cancer: Non-Invasive II on Saturday, May 13 from 8:30 am EDT to 8:40 am EDT
Poster presentation based on abstract title: MP98-05: Checkpoint Inhibition with Systemic Anti-Programmed Cell Death Ligand-1 and Intravesical TMX-101 (Vesimune) Decrease Tumor Burden in a Mouse Model of Urothelial Carcinoma
Presenting Author: Andrew T. Lenis MD MS, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California
Session: Bladder Cancer: Basic Research & Pathophysiology on Tuesday, May 16 from 9:30 am EDT to 11:30 am EDT
About UroGen Pharma Ltd.
UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
CONTACT: Gary Titus, UroGen Pharma Ltd. 689 Fifth Avenue, 14th Floor New York, NY 10022 [email protected] 646-768-9531 Stephanie Carrington, ICR, Inc. 685 Third Avenue, 2nd Floor New York, NY 10017 [email protected] 646-277-1282
